Health Condition 1: null- Breast Cancer (Retrospective data of Breast Cancer Patients will be collected)
Conditions
Interventions
None listed
Sponsors
Not applicable Thesis Protocol
Eligibility
Inclusion criteria
Inclusion criteria: Female breast cancer patients referred for 18[F] FDGPET/CT scan in the Nuclear Medicine Department of Max Super Speciality Hospital.
Exclusion criteria
Exclusion criteria: Patient clinical data not available.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1.To determine 18[F] FDG PET/CT effectiveness in the evaluation of chemotherapy response by calculating the percentage decrease in SUV value from the baseline value (Pre-therapy scan). 2. To determine the impact of 18[F] FDG PET/CT on the treatment management plan, whether altered or supported. 3. To determine the most common metastatic site in the metastatic breast cancer patients. Timepoint: 1.Percentage decrease in SUV value (post-therapy scan) from the baseline value (Pre-therapy scan). 2.Change in the treatment management plan. 3. Most common metastatic site in the metastatic breast cancer patients. | — |
Primary
| Measure | Time frame |
|---|---|
| To determine the indication for 18[F] FDG PET/CT for breast cancer patients, used by Oncologist in Max Super Speciality Hospital: a)Diagnosis b)Staging c)Recurrence/Metastasis (Restaging) d)Treatment response evaluation e)Radiation treatment response Timepoint: Indication of 18[F] FDG PET/CT for breast cancer patients: a)Diagnosis b)Staging c)Recurrence/Metastasis (Restaging) d)Treatment response evaluation e)Radiation treatment response | — |
Countries
India
Contacts
Public Contactpriya gupta
DIPSAR
Outcome results
None listed